tirzepatide + l-arginine Dual Agonist (GLP-1/GIP) Assessing the therapeutic potential of

Repeat testing at 4-8 weeks helps assess individual response and tolerability before dose adjustment

Semaglutide was approved in 2022 for use alongside lifestyle changes in pediatric patients aged 12 or older with an initial BMI equal to or greater than the 95th percentile for their age and sex

We can't stress this enough: the storage guidelines for an unopened vial and an opened vial are completely different

Allulose can be a unique functional sweetener because of its anti-obesity, anti-hyperglycemic, anti-lipidemia, and anti-diabetes properties

Check in with your provider as your treatment progresses

However, its not currently approved specifically for weight loss